TreatSMA on Tour – U.K.
It is becoming more apparent than ever that there is a lack of access to physiotherapists for children and adults in the community that specialise in SMA or have knowledge of and training in the condition.
UK campaign for access to treatments and support for those with spinal muscular atrophy
BLOG ARCHIVE
Physio with Marion – ‘Choosing a private physiotherapist for you or your child (In the UK)’ document now available
The powerpoint slide Marion used in the latest episode of Physio with Marion titled Choosing a private physiotherapist for you or your child (In the UK) is now available as a PDF document.
Treatsma website reaches national news in Bhutan
Treatsma website reaches national news in Bhutan.
Treatsma website reaches national news in Bhutan
Treatsma website reaches national news in Bhutan.
Update on Roche’s SMA global clinical development programme: New global combination study to begin in early 2022
We are pleased to share with you the initiation of MANATEE, a new global Phase 2/3 clinical study that aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in Spinal Muscular Atrophy (SMA).
Update on Roche’s SMA global clinical development programme: New global combination study to begin in early 2022
We are pleased to share with you the initiation of MANATEE, a new global Phase 2/3 clinical study that aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in Spinal Muscular Atrophy (SMA).
Living with SMA – Hitting Our Fourties
TreatSMA Trustee Andi Thornton speaks with SMA UK Trustee Toby Mildon about mental health, treatments, University and work, health care and much more
Living with SMA – Hitting Our Fourties
TreatSMA Trustee Andi Thornton speaks with SMA UK Trustee Toby Mildon about mental health, treatments, University and work, health care and much more
New trial announced by Biogen
New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam)